Overview

Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD BMS-986369, Rituximab +/- Nivolumab.

Status:
Not yet recruiting
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
First line treatment with combination rituximab and BMS-986369 with, or without nivolumab, in patients in previously untreated Follicular Lymphoma
Phase:
Phase 2
Details
Lead Sponsor:
Olivia Newton-John Cancer Research Institute
Collaborators:
Austin Health
Barwon Health
Bristol-Myers Squibb
Eastern Health
Fiona Stanley Hospital
Grampians Health
Treatments:
Nivolumab
Rituximab